The Medical Letter on Drugs and Therapeutics
Vancomycin Dosing and Monitoring
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Revised: 4/6/09: Dosing paragraph: The next to last sentence should be "...organism is ≥2 mg/L, the new...." (not >2 mg/L).

Consensus recommendations for dosing and therapeutic monitoring of intravenous (IV) vancomycin (Vancocin, and others) were recently published.1 IV vancomycin has been used for decades as an alternative to penicillins for treatment of serious infections due to gram-positive cocci. In recent years, the widest use of the drug has been for treatment of serious methicillin-resistant Staphylococcus aureus (MRSA) infections.2

TOXICITY — Earlier formulations of vancomycin, which contained many impurities, were associated with infusion reactions, nephrotoxicity and ototoxicity. Current formulations, however, appear to be generally free of these toxicities, at least when the standard dose is used and the patient has normal renal function and is not taking a nephrotoxic drug (such as an aminoglycoside) concurrently. The most common adverse effects, such as fever, chills and ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Vancomycin Dosing and Monitoring
Article code: 1309a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian